CD274 and non-small cell lung carcinoma: Other secondary endpoints include the objective response rate and duration of response by BICR per RECIST v1.1, PFS2, patient-reported outcomes in the TROP2 NMR-positive population and FAS, and safety.<h4>Discussion</h4>TROPION-Lung10 will assess first-line Dato-DXd plus rilvegostomig in patients with advanced/metastatic NSCLC with high PD-L1 expression and without AGAs.<h4>Clinical trial registration</h4>ClinicalTrials.gov, identifier NCT06357533.